Upload
serena
View
28
Download
2
Tags:
Embed Size (px)
DESCRIPTION
Drugs for Bipolar Disorders. Kaukab Azim, MBBS, PhD. Drug List. Learning Outcomes. By the end of the course the students should be able to Explain the mechanism of action of drugs used in acute mania Explain the mechanism of action of lithium Describe the main pharmacokinetics of lithium - PowerPoint PPT Presentation
Citation preview
Drugs for Bipolar Disorders
Kaukab Azim, MBBS, PhD
Drug List
For Treatment of Acute Mania For Maintenance TreatmentFirst Line Drugs Second Line Drugs First Line Drugs Second Line Drugs
Lithium Carbamazepine* Lithium Carbamazepine*
Valproate* Lamotrigine* Valproate*
Olanzapine* Lamotrigine*
Quietapine* Olanzapine*
Risperidone*
Aripiprazole*
Haloperidol*
Clozapine*
* These drugs have been mentioned in other lectures
Learning Outcomes
By the end of the course the students should be able to
Explain the mechanism of action of drugs used in acute mania Explain the mechanism of action of lithium Describe the main pharmacokinetics of lithium Describe the adverse effects of lithium. Outline the main drug interactions of lithium. Outline the main contraindications of lithium Describe the main therapeutic uses of lithium. Outline the therapeutic uses of valproate, an carbamazepine in bipolar
disorder. Outline the use of neuroleptics in bipolar disorder.
Classification of Bipolar Disorders*Type Features
Bipolar disorder type 1 A manic episode ± major depressive or mixed episode
Bipolar disorder type 2 A major depressive episode ± hypomanic episode
Cyclothymic disorderChronic fluctuation between subsyndromal and hyomanic episodes (at least 2 years for adults)
Bipolar disorder not other wise specified Any bipolar disorder that does not meet criteria for any specific bipolar disorder
* From DSM iV text revision
Theories of Bipolar DisorderGenetic factors• 80-90% of patients with bipolar disorder have a biologic relative
with a mood disorder.• The concordance rate of mood disorders is 60-80% for
monozygotic twins and 14-20% for dizygotic twins.
Non-genetic factors• Stressful life events often precede mood episodes and can
increase recurrence rate of them.• Changes in sleep -wake cycle can precipitate episodes of mania.• Bright light therapy, used in the treatment of winter depression
can precipitate ipomania.
Neurotransmitter/neuroendocrine theories
Monoamine hypothesis• An excess of catecholamines (primarily NE an DA) can cause
mania.• Deficit of monoamines (primarily NE , DA and/or 5-HT) can
cause depression.Cholinergic hypothesis• Drug that increase cholinergic activity can decrease manic
symptomsDysregulation of amino acid neurotransmitters• Drugs that increase GABA activity or decrease glutamate
activity are used for treatment of mania (lithium, lamotigrine, valproic acid)
Theories for Bipolar DisorderDysregulation of secondary messenger system• Abnormal adenyl cyclase activity, abnormal
phosphoinositide responses, abnormal Na+, K+ and Ca++ channel exchanges.
Dysregulation of hypothalamic, pituitary, thyroid axis.• Hyperthyroidism can precipitate manic symptoms• Hypothyroidism can trigger depression and is a risk
factor for rapid cycling.Sensitization and kindling• Recurrences of mood episodes causes
electrophysiological kindling an can result in rapid or continuous mood cycling.
LithiumDrug• Lithium is a small monovalent cation (MW:
6.9).Main mechanisms of action• Li+ is classified as a mood-stabilizing drug
because it can reduce both manic and depressive symptoms of bipolar disorder.
The precise mechanism of its therapeutic effect is unknown but is likely related to inhibition of two signal transduction pathways:
1) Inositol signaling• Li+ inhibits inositol monophosphatase, the rate-limiting
enzyme involved in inositol recycling. This leads to:– Depletion of phosphatidylinositol-4,5-bisphosphate
( PIP2) which is the precursor of IP3 and DAG– Inhibition of the synthesis of IP3 and DAG– Inhibition of the activity of many receptors that are
IP3/DAG linked.
This is the major current working hypothesis for lithium therapeutic mechanism of action
Lithium2) Glycogen synthase kinase-3 signaling– Li+ inhibits glycogen synthase kinase-3, a protein-
kinase that regulate signal pathways involved in apoptosis.
– suppression of the expression of pro-apoptotic genes and increase expression of anti-apoptotic genes.
– The ultimate effect is neuro-protection which could underlie long term mood stabilization (increased neurogenesis has been found in the hippocampus after lithium treatment)
Additional mechanisms of action
1) Actions on other second messenger systems• Li+ inhibits norepinephrine-sensitive adenyl cyclase, which
results in a decrease of cAMP.• Li+ enhances GABAergic activity and reduces glutamatergic
activity2. Actions on electrolytes and ion transport• Li+ can mimic the role of Na+ in excitable tissues.• It goes across cell membranes an Na+ sodium in action
potential.• It is not pumped out by Na+/K+ ATPase and therefore it
tends to accumulate inside the cells, displacing Na+.• Ca++/Na+ exchanger is not significantly affected at
therapeutic concentration
Effect of lithium on the IP3 (inositol trisphosphate) and DAG (diacylglycerol) second-messenger system. The schematic diagram shows the synaptic membrane of a neuron. (PIP2, phosphatidylinositol-4,5-bisphosphate; PLC, phospholipase-C; G, coupling protein; Effects, activation of protein kinase C, mobilization of intracellular Ca2+, etc.) Lithium, by inhibiting the recycling of inositol substrates, may cause depletion of the second-messenger source PIP2 and therefore reduce the release of IP3 and DAG. Lithium may also act by other mechanisms. (Katzung 2011)
Lithium
Pharmacological effectsCNS effects• At therapeutic doses Li+ has no mental effects on normal
individual.• The calming effect in manic patients develops slowly (several
day or weeks).
Cardiovascular effects• Depression of the SA node• T wave depression or inversion (likely due to intracellular
myocardial K+ depletion by displacement with Li+).
Renal effects• Inhibition of vasopressin action on the kidney (likely due to
inhibition of adenyl cyclase)
Lithium
Endocrine and metabolic effects• Inhibition of thyroid hormone synthesis (TSH-induced production of
cAMP in thyroid cells is inhibited, due to inhibition of adenylyl cyclase)
• ECF expansion (during the first days of therapy. Li+ tends to accumulate inside the cells, displacing Na+).
Pharmacokinetics• Oral bioavailability: 100%• Distribution in total body water (Vd . 45 L)• No metabolism• Excretion: 97% in the urine (80% is reabsorbed in the proximal
tubule, some is reabsorbed in the collecting duct).• Half -life: 20 hours
(Accumulation can be a problem due to the long half life)
Lithium
CNS• Fine hand tremor (up to 50%. Beta-blockers can be
useful)• Memory impairment, mental confusion, poor
concentration (up to 40%)• Muscle weakness, lethargy (up tp 30%)• Motor hyperactivity, ataxia, aphasia, seizures (with
high doses).Metabolic/Endocrine system• Hypothyroidism (5-8%)• Weight gain (up to 30%)
Lithium Adverse effects
Urinary system• Polyuria, polydipsia (up to 70%)• Nephrogenic diabetes insipidus (12% after long term
treatment).Gastrointestinal system• Nausea, epigastric bloating, diarrhea (6-20%).Adverse effects Cardiovascular system• Edema, frequent during the first 5-7 days of therapy (likely
due to increased NA+ in the ECF).• Hypotension, arrhythmias sinus bradycardia, SA / AV blockOther systems• Leukocytosis (very frequent)• Acneiform skin eruptions
Overdosage• Li+ has a narrow therapeutic index (about 2-3) and Li+
plasma levels must always be monitored.• Symptoms of overdosage include lethargy, apathy,
unsteady gait, mental confusion, muscle twitches, seizures, stupor, coma and cardiovascular collapse.
Pregnancy• Disagreement exists about the importance of
teratogenic effects of Li+• However the drug is rated pregnancy category D by FDA• Ebstein’s anomaly of the tricuspid valve is the main
teratogenic effect.
Drug interactions of Clinical ImportanceDrug Type of Interaction
Thiazides, Loop diureticsIncreased Li+ plasma levels (increased Na+ elimination enhances Li+ reabsorption in the proximal tubules)
NSAIDsIncreased Li+ plasma levels (reduced renal prostaglandin production decreases renal elimination of Li+)
ACE inhibitors, angiotensin blockers (ARBs)
Increased Li+ plasma levels (mechanism is unknown)
SSRIs Serotonin syndrome may occur (mechanism is unknown)
CarbamazepineIncreased neurotoxicity of Li+ (ataxia, tremor, hyperreflexia. Mechanism is unknown
Iodide salts Risk of Li+ induced hypothyroidism is increased
Main uses
Manic phase of bipolar disorders (often with concurrent use of antipsychotics or benzodiazepines during the first few days)
Maintenance treatment of bipolar disorder (maintenance treatment can prevents or diminishes the intensity of subsequent episodes of both mania and depression. Treatment must be continued for at least 6-9 months; in severe cases even for life).
Schizoaffective disorder (together with antipsychotic drugs).
Depressive disorder (augmenting agent for antidepressants).
Lithium Therapeutic uses
Unlabeled/Investigational uses Aggression, post-traumatic stress disorder,
conduct disorder in children
Anticonvulsants for Bipolar DisorderDrugs• Valproate, lamotigrine and carbamazepine are the main
anticonvulsant drugs with mood stabilizing properties.
Mechanism of action
• Still uncertain. Actions similar to those of Li+, which seems to mediate the mood stabilizing properties include:
a. Inhibition of adenylyl cyclase
b. Reduction of inositol generation in the inositol signaling pathway
c. Activation of neuroprotective genes
Pharmacological and adverse effects
(these are discussed under antiseizure drugs)
Therapeutic uses in bipolar disorders
• As monotherapy in acute mania or mixed states• As monotherapy in acute bipolar depression• As maintenance therapy
Atypical Neuroleptics for Bipolar Disorder
Drugs
• Aripiprazole, olanzapine, quetiapine, risperidone.
Mechanism of action, pharmacological and adverse effects
• (these are discussed under neuroleptic drugs)
Therapeutic uses in bipolar disorders
• As monotherapy or adjunctive therapy in acute mania or mixed states
• As adjunctive therapy in acute bipolar depression (risperidone, olanzapine)
Therapy for Bipolar DisorderDisorder First Line Drugs Second Line Drugs
Acute Mania or mixed states
LithiumValproateCarbamazepineAripiprazoleOlanzapineQuetiapineRisperidone
Lamotrigine (for rapid cycling)
Acute bipolar depressionLithiumLamotrigineCarbamazepine
Valproate
Maintenance therapyLithiumValproateLamotrigineOlanzapine
Carbamazepine
Therapy for Bipolar Disorder
Hypomania
Lithium or valproate or carbamazepine(if response is inadequate)
Lithium plus an anticonvulsant or an atypical neuroleptic
Mania
Lithium or valproate plus lorazepam(if response is inadequate)
Lithium plus an anticonvulsant plus an atypical neuroleptic
Mild bipolar depression Lithium or lamotrigine
Severe bipolar depressionLithium plus an SSRI
(if response is inadequate)Lithium plus lamotrigine plus an SSRI